-
Research spotlight: Use of glucose-lowering SGLT2i drugs may help patients with gout and diabetes take fewer medications
03 Feb 2026 03:11 GMT
… medications in different classes to treat both. This makes treatment … pill burden for patients and the potential for drug … Population-Based Target Trial Emulation Studies
Article Publication … Chem, Horizon, Shanton and Protalix.
Disclaimer: AAAS and EurekAlert …
-
Sanofi records win and loss with rare disease drug in Phase III trials
02 Feb 2026 21:47 GMT
… critical unmet medical needs. A daily pill could make … FDA include Takeda’s Replagal (agalsidase alfa), and Chesi and Protalix … migalastat). The drug will soon fall into BioMarin Pharmaceutical’s ownership … company of the Clinical Trials Arena.
Sign up for …
-
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy
30 Jan 2026 19:25 GMT
… /iStock via Getty Images
Protalix BioTherapeutics (PLX) said on Friday … expert panel of the European Medicines Agency (EMA), endorsed a new … replacement therapy developed by the biotech with its Italian partner Chiesi …
-
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
30 Jan 2026 14:47 GMT
… immediately and initiate appropriate medical treatment. In patients with severe … the FDA and the EMA in May 2023. Protalix’s … proteins that target established pharmaceutical markets: PRX–115, … trials; the inherent risks and uncertainties in developing drug …
-
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
30 Jan 2026 14:47 GMT
… alfa. The Committee for Medicinal Products for Human Use … testament to Protalix’ s commitment to advancing treatments for people … proteins that target established pharmaceutical markets: PRX–115, … trials; the inherent risks and uncertainties in developing drug …
-
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
30 Jan 2026 14:47 GMT
… alfa. The Committee for Medicinal Product for Human Use … testament to Protalix’s commitment to advancing treatments for people … proteins that target established pharmaceutical markets: PRX–115, … trials; the inherent risks and uncertainties in developing drug …
-
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2025 Earnings Call Transcript
14 Nov 2025 13:52 GMT
… , and welcome to the Protalix BioTherapeutics, Inc. Third Quarter … by the Committee of Medicinal Products for Human Use … treatment of uncontrolled gout. Preparation for the phase two clinical trial … become effective following the FDA’s standard thirty-day …
-
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
05 Nov 2025 15:50 GMT
… behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or “the Company … pertinent to investors. Protalix and Chiesi Global Rare … that the Committee for Medicinal Products for Human Use … (CHMP) of the European Medicines Agency (EMA) has issued …
-
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
03 Nov 2025 21:30 GMT
… immediately and initiate appropriate medical treatment. In patients with … FDA and the European Medicines Agency in May 2023. Protalix … that target established pharmaceutical markets, including the … trials; the inherent risks and uncertainties in developing drug …
-
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
17 Oct 2025 10:58 GMT
… immediately and initiate appropriate medical treatment. In patients with … FDA and the European Medicines Agency in May 2023. Protalix … that target established pharmaceutical markets, including the … trials; the inherent risks and uncertainties in developing drug …
About
© 1995-2026